US 11,667,719 B2
VHH immunoglobulin chain variable domain that binds to IL-7R and methods of use thereof for treating autoimmune and/or inflammatory diseases
Scott Crowe, Cambridge (GB); Mike West, Cambridge (GB); Kevin Roberts, Cambridge (GB); Tim Carlton, Cambridge (GB); Luana Maggiore, Cambridge (GB); Marion Cubitt, Cambridge (GB); Lurdes Duarte, Cambridge (GB); Martyn Symmons, Cambridge (GB); and Keith Ray, Cambridge (GB)
Assigned to SORRISO PHARMACEUTICALS, INC., San Diego, CA (US)
Filed by SORRISO PHARMACEUTICALS, INC., San Diego, CA (US)
Filed on May 24, 2022, as Appl. No. 17/752,710.
Application 17/752,710 is a continuation of application No. 17/620,030, previously published as PCT/GB2020/051496, filed on Jun. 19, 2020.
Claims priority of application No. 19181868 (EP), filed on Jun. 21, 2019.
Prior Publication US 2022/0363769 A1, Nov. 17, 2022
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2866 (2013.01) [C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 16 Claims
 
1. A VHH that binds to IL-7R, wherein the VHH comprises:
(a) a complementarity determining region 1 (CDR1) comprising an amino acid sequence as set forth in SEQ ID NO: 1, a complementarity determining region 2 (CDR2) comprising an amino acid sequence as set forth in SEQ ID NO: 2, and a complementarity determining region 3 (CDR3) comprising an amino acid sequence as set forth in SEQ ID NO: 3; or
(b) a CDR1 comprising an amino acid sequence as set forth in SEQ ID NO: 71, a CDR2 comprising an amino acid sequence of any one as set forth in SEQ ID NOs: 72, 73, 74, or 75, and a CDR3 comprising an amino acid sequence of any one as set forth in SEQ ID NOs: 77 or 78;
wherein the VHH binds IL-7R.